Trial Profile
A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Results (n=3134) of safety data were pooled from seven randomized phase 3 trials, were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.